A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety, And Tolerability Of Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine

In this study,288 adult migraine patients aged 18-65 years (diagnosed with migraine without aura and/or migraine with aura, with at least a 1-year history)will be collected to evaluate the efficacy, safety and tolerability of Anisodine Hydrobromide in preventing migraine attacks in episodic migraine in adults.

Start Date30 Oct 2023

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

CTR20222106 / RecruitingPhase 3

氢溴酸樟柳碱注射液治疗急性缺血性脑卒中的有效性和安全性——前瞻性、多中心、随机、双盲、安慰剂平行对照临床试验

[Translation] Efficacy and safety of anisodine hydrobromide injection in the treatment of acute ischemic stroke: a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial

（1）主要目的：在静脉溶栓治疗的基础上，评价氢溴酸樟柳碱注射液与安慰剂平行对照治疗发病24小时内的急性缺血性脑卒中患者的有效性。（2）次要目的：在静脉溶栓治疗的基础上，评价氢溴酸樟柳碱注射液与安慰剂平行对照治疗发病24小时内的急性缺血性脑卒中患者的安全性。

[Translation]

(1) Primary objective: To evaluate the effectiveness of anisodine hydrobromide injection in parallel with placebo in the treatment of patients with acute ischemic stroke within 24 hours of onset, based on intravenous thrombolytic therapy. (2) Secondary objective: To evaluate the safety of anisodine hydrobromide injection in parallel with placebo in the treatment of patients with acute ischemic stroke within 24 hours of onset, based on intravenous thrombolytic therapy.

Start Date09 Nov 2022

Sponsor / Collaborator

Chengdu First Pharmaceutical Co. Ltd.

ChiCTR2300074040 / RecruitingPhase 3IIT

Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of anisodine hydrobromide injection in the treatment of acute ischemic stroke

Start Date01 Oct 2022

Sponsor / Collaborator-

100 Clinical Results associated with Anisodine Hydrobromide

100 Translational Medicine associated with Anisodine Hydrobromide

100 Patents (Medical) associated with Anisodine Hydrobromide

Literatures (Medical) associated with Anisodine Hydrobromide

01 Jan 2024·Frontiers in medicine

Purtscher-like retinopathy and paracentral acute middle maculopathy associated with improper antihypertensive drug use: a case report.

Article

Author: Tian, Miao ; Sawut, Abdulla ; Cai, Liwei ; Li, Ying ; Chen, Changzheng ; Meng, Yang ; Xiao, Di ; Yi, Zuohuizi

BackgroundPurtscher-like retinopathy (PLR) is a rare retinal microangiopathy with unclear pathogenesis. Paracentral acute middle maculopathy (PAMM) is an optical coherence tomography (OCT) sign proposed in recent years, which is characterized by infarction of the middle layer of the retina. This article reported a rare case of PRL and PAMM probably related to improper antihypertensive drug use in a middle-aged male.Case presentationA 49-year-old man presented with a complaint of sudden-onset vision loss and paracentral scotomas in the right eye for approximately 1 week. At presentation, the best-corrected visual acuity (BCVA) was 20/63 OD and 20/20 OS. Fundus examination showed multiple cotton-wool spots and Purtscher flecken in the posterior segment of the right eye. OCT revealed hyper-reflectivities in the inner nuclear layer (INL), consistent with PAMM. En face OCT showed PAMM's characteristic "fern-like" perivenular changes. Fluorescein angiography demonstrated prolonged arm-to-retina time, delayed artery and venous filling, and hypofluorescence corresponding to cotton-wool spots. Examinations of the left eye were unremarkable. Many imaging and laboratory tests were performed to detect the possible cause of PLR and PAMM, but no possible explanation was found except improper antihypertensive drug use. The patient was recommended to stop his antihypertensive medication, and prescribed other systemic medicines, including oral prednisolone (40 mg q.d. with gradual tapering), oral cobalamin (0.5 mg t.i.d.), and subcutaneous injections of compound anisodine (2.0 mL q.d.) beside the superficial temporal artery. Two weeks after onset, his BCVA improved to 20/25 in the right eye. During follow-ups, his BCVA recovered to 20/20, accompanied by the regression of fundus lesions. The patient reported no treatment-related adverse effects.ConclusionThis is the first reported case of PLR and PAMM following improper antihypertensive drug use. Our report expands our understanding of the etiology and pathophysiology of PLR and PAMM. We also stress the importance of proper application of medications in clinical practice.

01 Feb 2021·Food ChemistryQ1 · AGRICULTURAL & FORESTRY SCIENCE

Indirect competitive enzyme-linked immunosorbent assay based on a broad-spectrum monoclonal antibody for tropane alkaloids detection in pig urine, pork and cereal flours

Q1 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Zhang, Yanfang ; Wang, Jianyi ; Wang, Zile ; Xiong, Jincheng ; Zheng, Pimiao ; Ren, Zhenhui ; He, Shuang ; Jiang, Haiyang

In this study, an indirect competitive enzyme-linked immunosorbent assay (ic-ELISA) based on a broad-spectrum monoclonal antibody for tropane alkaloids (TAs) was established for the rapid screening of atropine, scopolamine, homatropine, apoatropine, anisodamine, anisodine and L-hyoscyamine residues in pig urine, pork and cereal flour samples through a simple sample preparation procedure. The half inhibitory concentrations of atropine, homatropine, L-hyoscyamine, apoatropine, scopolamine, anisodamine and anisodine were 0.05, 0.07, 0.14, 0.14, 0.24, 5.30 and 10.15 ng mL^-1, respectivelyThe detection and quantitative limits of this method for TAs in samples were 0.18-73.18 and 0.44-74.77 μg kg^-1. The spiked recoveries ranged from 69.88% to 147.93%, and the coefficient of variations were less than 14%. Good correlation (R² = 0.9929) between the results of the ic-ELISA and the high performance liquid chromatography-tandem mass spectrometry support the reliability of the developed ic-ELISA method.

01 Nov 2020·International Journal of NeuroscienceQ4 · MEDICINE

Vision treatment strategy for acute blindness in adolescent female with diffuse leptomeningeal glioneuronal tumor

Q4 · MEDICINE

Article

Author: Bao, Yi ; Zhou, Siqin ; Wang, Ying ; Wu, Huihui ; Zhang, Miao ; Liu, Guangjian

Diffuse leptomeningeal glioneuronal tumor with the first symptom of acute rapid blindness in both eyes are rare in adolescents. We present a case of an adolescent female without a history of cancer who developed a dramatic loss of vision and eventually blindness, and was diagnosed as diffuse leptomeningeal glioneuronal tumor by cerebrospinal fluid cytology and enhanced MRI. In order to save vision, under the condition of ineffective dehydration treatment, timely emergency surgery to implant Ommaya sac drainage cerebrospinal fluid. According to the pathophysiological mechanism of cerebral edema, we added Edaravone to scavenge oxygen free radicals, Alprostadil to improve microcirculation, Monosialotetrahexosylganglioside nutrient nerve, Butylphthalide to promote collateral circulation, combined with hyperbaric oxygen and acupoint injection of Anisodine. Finally, the patient's vision returned to normal. Conclusion: when dehydration treatment is ineffective, timely surgery to reduce intracranial pressure, combined with comprehensive treatment, can effectively save vision.

100 Deals associated with Anisodine Hydrobromide

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Ischemic Stroke	CN	Chengdu First Pharmaceutical Co. Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis